Scholar Rock Holding (SRRK) Total Current Liabilities (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Total Current Liabilities came in at $59.6 million in Q1 2026, up 58.73% year-on-year from $37.6 million in Q1 2025, and up 7.62% quarter-over-quarter from $55.4 million in Q4 2025.
Scholar Rock Holding (SRRK) Total Current Liabilities (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Total Current Liabilities history runs 10 years deep, the most recent figure standing at $59.6 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 58.73% year-over-year to $59.6 million in Q1 2026; TTM through Mar 2026 was $59.6 million, a 58.73% increase from a year earlier, with the FY2025 full-year figure at $55.4 million, up 18.07% from the prior year.
- Total Current Liabilities climbed to $59.6 million in Q1 2026 per SRRK's latest filing, from $55.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $62.0 million in Q3 2025 and bottomed at $24.3 million in Q2 2023.
- The 5-year median for Total Current Liabilities is $37.5 million (2024), against an average of $39.7 million.
- Across the five-year window, Total Current Liabilities slumped 52.29% in 2022 and soared 58.73% in 2026, its largest moves.
- Year by year, Total Current Liabilities stood at $36.4 million in 2022, then declined by 10.03% to $32.7 million in 2023, then soared by 43.36% to $46.9 million in 2024, then advanced by 18.07% to $55.4 million in 2025, then advanced by 7.62% to $59.6 million in 2026.
- Per Business Quant, the three latest SRRK Total Current Liabilities figures stand at $59.6 million (Q1 2026), $55.4 million (Q4 2025), and $62.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | 59.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.64 Mn |
| Dec 31, 2025 | 55.42 Mn |
| Sep 30, 2025 | 61.97 Mn |
| Jun 30, 2025 | 50.44 Mn |
| Mar 31, 2025 | 37.57 Mn |
| Dec 31, 2024 | 46.94 Mn |
| Sep 30, 2024 | 39.37 Mn |
| Jun 30, 2024 | 32.99 Mn |
| Mar 31, 2024 | 37.51 Mn |
| Dec 31, 2023 | 32.74 Mn |
| Sep 30, 2023 | 26.73 Mn |
| Jun 30, 2023 | 24.27 Mn |
| Mar 31, 2023 | 26.21 Mn |
| Dec 31, 2022 | 36.39 Mn |
| Sep 30, 2022 | 33.74 Mn |
| Jun 30, 2022 | 40.16 Mn |
| Mar 31, 2022 | 33.37 Mn |
| Dec 31, 2021 | 64.30 Mn |
| Sep 30, 2021 | 64.60 Mn |
| Jun 30, 2021 | 67.02 Mn |